Immunogenicity of the hepatitis A vaccine 20 years after infant immunization.
Abstract
To determine the duration of immunity provided by the Hepatitis A vaccination (HepA), we evaluated a cohort of participants in Alaska 20 years after being immunized as infants. At recruitment, participants received two doses of inactivated HepA vaccine on one of three schedules. We conducted hepatitis A antibody (anti-HAV) testing for participants at the 20-year time-point. Seventy-five of the original 183 participants (41%) were available for follow-up. The overall anti-HAV geometric mean concentration was 29.9 mIU/mL (95% CI 22.4 mIU/mL, 39.7 mIU/mL) and 50 participants (68%) remained seropositive (titer ≥ 20 mIU/mL). Using a fractional polynomial model, the predicted percent seropositive at 25 years was 55.3%, 49.8% at 30 years and 45.7% at 35 years, suggesting that the percent sero-positive could drop below 50% earlier than previously expected. Further research is necessary to understand if protection continues after seropositivity diminishes or if a HepA booster dose may become necessary.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-HAV persistence of >20 years was demonstrated among immunocompetent adults vaccinated with a 2-dose hepatitis A schedule as adults.
“Anti-HAV persistence of >20 years was demonstrated among immunocompetent adults vaccinated with a 2-dose hepatitis A schedule as adults (1303,1305).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1305]
Cites
Clinical manifestations and diagnosis of hepatitis A virus infection
Koff, R. S. (1992) · Vaccine · doi:10.1016/0264-410x(92)90533-p · Cited by 188 · see citing works
Ly, K. N., & Klevens, R. M. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu834 · Cited by 101 · see citing works
The role of young children in a community-wide outbreak of hepatitis A
Smith, P. F., Grabau, J. C., Werzberger, A., Gunn, R. A., Rolka, H., Kondracki, S. F., Gallo, R. J., & Morse, D. L. (1997) · Epidemiology and Infection · doi:10.1017/s0950268897007462 · Cited by 100 · see citing works
Doshani, M., Weng, M., Moore, K. L., Romero, J. R., & Nelson, N. P. (2019) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6806a6 · Cited by 75 · see citing works
Immunogenicity of an Inactivated Hepatitis A Vaccine in Infants and Young Children
Bell, B. P., Negus, S. E., Fiore, A. E., Plotnik, J. N., Dhotre, K. B., Williams, J. L., Shapiro, C. N., & McMahon, B. J. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000253253.85640.cc · Cited by 68 · see citing works
Self-citationSpradling, P. R., BULKOW, L. R., Negus, S. E., Homan, C., Bruce, M. G., & McMahon, B. J. (2015) · Hepatology · doi:10.1002/hep.28375 · Cited by 18 · see citing works
Self-citationEpson, E. E., Cronquist, A., Lamba, K., Kimura, A. C., Hassan, R., Selvage, D., McNeil, C. S., Varan, A. K., Silvaggio, J., Fan, L., et al. (2016) · Public Health · doi:10.1016/j.puhe.2016.03.027 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 2,759 · see citing works
- Authors
- Mosites, E., Seeman, S., Negus, S., Homan, C., Morris, J., Nelson, N. P., Spradling, P. R., Bruce, M., & McMahon, B.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Alaska Native Tribal Health Consortium (US)
- Corresponding author
- Mosites, E.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 38
- Issue
- 32
- Pages
- 4940-4943
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W3034359753
- Cited by
- 11
- References
- 7
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- hepatitis A vaccine, immunogenicity, duration of immunity, anti-HAV antibodies, seropositivity, long-term follow-up, booster vaccination, inactivated vaccine, fractional polynomials, infant immunization
- MeSH terms
- Alaska, Hepatitis A, Humans, Immunization Schedule, Immunization, Secondary, Infant, Vaccination, Vaccines, Inactivated, Hepatitis A Vaccines, Hepatitis A Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
